Converging evidence has linked the anterior mid-cingulate cortex to negative affect, pain and cognitive control. It has previously been proposed that this region uses information about punishment to control aversively motivated actions. Studies on the effects of lesions allow causal inferences about brain function; however, naturally occurring lesions in the anterior mid-cingulate cortex are rare. In two studies we therefore recruited 94 volunteers, comprising 15 patients with treatment-resistant depression who had received bilateral anterior cingulotomy, which consists of lesions made within the anterior mid-cingulate cortex, 20 patients with treatment-resistant depression who had not received surgery and 59 healthy control subjects. Using the Ekman 60 faces paradigm and two Stroop paradigms, we tested the hypothesis that patients who received anterior cingulotomy were impaired in recognizing negative facial affect expressions but not positive or neutral facial expressions, and impaired in Stroop cognitive control, with larger lesions being associated with more impairment. Consistent with this hypothesis, we found that larger volume lesions predicted more impairment in recognizing fear, disgust and anger, and no impairment in recognizing facial expressions of surprise or happiness. However, we found no impairment in recognizing expressions of sadness. Also consistent with the hypothesis, we found that larger volume lesions predicted impaired Stroop cognitive control. Notably, this relationship was only present when anterior mid-cingulate cortex lesion volume was defined as the overlap between cingulotomy lesion volume and Shackman’s meta-analysis-derived binary masks for negative affect and cognitive control. Given substantial evidence from healthy subjects that the anterior mid-cingulate cortex is part of a network associated with the experience of negative affect and pain, engaging cognitive control processes for optimizing behaviour in the presence of such stimuli, our findings support the assertion that this region has a causal role in these processes. While the clinical justification for cingulotomy is empirical and not theoretical, it is plausible that lesions within a brain region associated with the subjective experience of negative affect and pain may be therapeutic for patients with otherwise intractable mood, anxiety and pain syndromes.

1 School of Medicine (Neuroscience), Ninewells Hospital and Medical School, University of Dundee, UK
2 Advanced Interventions Service, Area 7, Level 6, South Block, Ninewells Hospital and Medical School, UK
3 School of Psychology and Neuroscience, University of St Andrews, St Andrews, UK

Correspondence to: Prof. Douglas Steele MD PhD MRCPsych,
School of Medicine (Neuroscience),
University of Dundee,
Ninewells Hospital and Medical School,
Dundee, DD1 9SY, UK
E-mail: d.steele@dundee.ac.uk

Keywords: mid-cingulate cortex; treatment-resistant depression; cingulotomy; cognitive control

Abbreviations: ACING = anterior cingulotomy; aMCC = anterior mid-cingulate cortex; EFS = Emotional Face Stroop task; HAD = Hospital Anxiety and Depression Scale; HAM-17 = 17-item Hamilton Depression Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; NART = National Adult Reading Test; OCD = obsessive compulsive disorder
Introduction

The anterior mid-cingulate cortex (aMCC) has been linked to cognitive control, negative affect and pain (Peyron et al., 2000; Vogt et al., 2003; Shackman et al., 2011). Considering negative affect, a recent review of animal and human neuroimaging studies concluded that the aMCC represents negative values produced by a punisher or non-reward and neural activity correlates with subjective unpleasantness (Vogt, 2014). Studies on the effects of lesions allow causal inferences about brain function. However, as a consequence of the pattern of arterial supply to the aMCC, naturally occurring lesions confined to the aMCC are extremely rare (Rauch et al., 2000; Shackman et al., 2011). We therefore investigated patients who received bilateral anterior cingulotomy (ACING), which consists of lesions in white matter deep to the aMCC (Rauch et al., 2000; Steele et al., 2008).

Consistent with recent reviews of aMCC function in healthy humans (Shackman et al., 2011; Vogt, 2014), one of the earliest uses of ACING was to treat otherwise intractable pain, with an early study noting that patients with comorbid anxiety and/or depression appeared to have the best outcomes (Foltz and White, 1962). ACING continues to be used for a small number of patients with intractable mood and/or obsessive compulsive disorder (OCD) (Rauch et al., 2000; Steele et al., 2008) and intractable pain (Pereira et al., 2014). It is important to note that the ACING procedure differs significantly between centres with, for example, some centres using a single bilateral lesion that may be repeated after a year depending on clinical response (Steele et al., 2008), and other centres using three bilateral lesions on a single occasion (Yang et al., 2014). In addition, the clinical indication (e.g. depressive illness, OCD or pain syndrome) differs complicating interpretation, as clinical syndromes such as mood disorder (Austin et al., 2001) and chronic pain (Schiltenwolf et al., 2014) are associated with cognitive impairment independent of lesions. Depressive illness, OCD and pain syndromes are highly comorbid, and neurosurgical comorbidity exclusion criteria are more clearly defined in some centres prior to neurosurgery (Steele et al., 2008) than others complicating interpretation of the literature.

The current literature on the neuropsychological effects of ACING consists of single case or small studies, with some reporting impairments in cognitive and emotional functioning. Cohen et al. (1999a) described the neuropsychological effects of ACING for intractable pain reporting deficits in sustained attention and response time. Janer and Pardo (1991) described ACING for mood disorder in one patient reporting selective attention deficits. Ridout et al. (2007) described four patients who had received ACING and five patients who had received a combination of anterior capsulotomy (ACAPS) and ACING, reporting impaired Stroop performance and impaired identification of emotional expressions. In a further study, five patients had received ACING and three had received both ACAPS and ACING for depressive illness, had postoperative improvement in two tasks (Paired Associates Learning and Spatial Working Memory) and no impairment in any neuropsychological task, perhaps due to recovery from illness (Steele et al., 2008). Ochsner et al. (2001) described the effects of ACING in a single patient with OCD and anorexia nervosa, describing visual and attentional deficits.

Therefore, while there have been reports of attentional impairments in patients with chronic pain after ACING (Cohen et al., 1999a, b), and general emotional recognition in a group of patients who had received both ACING and ACAPS (Ridout et al., 2007), there is limited evidence for the effects of lesions only within the aMCC. As there is considerable evidence for normal aMCC function being linked to negative affect and cognitive control (Shackman et al., 2011; Vogt, 2014), we predicted that lesions within the aMCC could result in specific impairments linked to these domains. Notably, interpersonal deficits are not apparent clinically in our patients. We were therefore predicting that more subtle impairments could be detected on neuropsychological testing. In testing these predictions we considered it important to correct for residual illness severity at the time of testing and be anatomically specific about the location of the aMCC with regard to negative affect and cognitive control.

Regarding anatomical specification of the aMCC, Shackman and colleague’s (2011) meta-analysis on studies of healthy subjects is notable because it was large, including data from 192 functional MRI studies with more than 3000 participants, and the authors have made available binary maps for negative affect, pain and cognitive control (http://neurovault.org/collections/474/), explicitly defining the spatial extent of aMCC functional neuroanatomy in Montreal Neurological Institute (MNI) anatomical space. We therefore used Shackman et al.’s (2011) masks to define aMCC functional neuroanatomy. We chose the Ekman 60 faces paradigm as it is a long-established emotional recognition task, and two Stroop paradigms.

We tested two main a priori hypotheses and two tests for map specificity. First, that increased volume of overlap between an ACING lesion and Shackman’s negative affect binary mask was associated with increased errors in recognizing negative emotional expressions, but not positive or neutral expressions. Second, we tested the hypothesis that increased volume of overlap between ACING lesions and Shackman’s cognitive control binary mask was associated with increased Stroop effect errors reflecting impaired cognitive control.

ACING lesions are primarily made within white matter aiming for the cingulum bundle but also have significant anatomical effects on adjacent grey matter (Steele et al., 2008). Shackman’s anatomical masks were derived from a meta-analysis of functional MRI studies of healthy subjects and most functional MRI signals are generated by grey matter. Neuropsychological impairments may be associated with grey matter, white matter or both. To test this,
our third hypothesis was that total lesion volume, involving both white and grey matter in contrast to grey matter linked volume defined by Shackman’s masks, would be associated with similar impairments as grey matter lesion volume alone.

Finally, Shackman et al. (2011) argued that negative affect, pain and cognitive control activate an overlapping region, the aMCC. However, their negative affect and cognitive control masks are not identical and they acknowledged that further work was required to determine whether negative affect, pain and cognitive control are anatomically coincident or subtly different in spatial distribution (Shackman et al., 2011). Therefore, our fourth hypothesis was that we would find similar negative affect recognition and cognitive control deficits, regardless of which of the two masks were used to calculate lesion overlap volume.

Materials and methods

Diagnosis was confirmed using the MINI PLUS (v5.0) (Sheehan et al., 1998) structured clinical interview and depressive illness severity quantified using the 17-item Hamilton Depression Rating Scale (HAM-17; Hamilton, 1960), the Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979) and the anxiety subscale of the Hospital Anxiety and Depression (HAD; Zigmond and Snaith, 1983) scale. Quality of life was assessed using the SF-36, a generic scale designed to assess aspects of health and well-being that are not disease, treatment or age-specific, consisting of eight multi-item components (Juenker et al., 2002). Here the eight components were averaged to give a single SF-36 score. IQ was estimated using the National Adult Reading Test (NART) and mood disorder treatment resistance quantified using the Massachusetts General Hospital Staging (MGH-S) method (Fava, 2003). The study was approved by the local ethics committee and written informed consent obtained from participants.

ACING is a long established neurosurgical stereotactic procedure for chronic treatment-refractory depressive illness, offered in the UK only when all other reasonable treatment strategies have failed, when the patient requests the operation, provided they are capable of informed consent (Steele et al., 2008). In Scotland, the suitability of and capacity to consent to the procedure is confirmed independently by medical and lay representatives of the Mental Welfare Commission with the Care Quality Commission undertaking a similar function in England. Patients who had received ACING for treatment-resistant depression were recruited from the Advanced Interventions Centre (AIS) in Dundee, an NHS UK-wide tertiary referral centre for treatment-resistant depression. Patients had received a single bilateral ACING lesion on at least one occasion as described (Steele et al., 2008) with approximately half the remaining patients receiving two bilateral lesions and one patient three bilateral lesions.

The emotional facial recognition task data were collected as part of a long-term ongoing longitudinal study (Study 1) on the neuropsychological assessment of patients receiving ACING. Twelve ACING patients participated (Surgical Patient Group 1, SPG1). The control data consisted of 38 participants (Control Group 1, CG1) without a history of mood disorder. Study 1 began over a decade ago. However some time ago we found that staff had stopped collecting Stroop data. Stroop data were therefore collected as part of a separate cross-sectional study (Study 2). Eight patients who had received one or more ACING procedures, and no other neurosurgical procedure (e.g. ACAPS), participated in Stroop testing (Patient Group 2, SPG2). In addition, we recruited a separate group of 20 patients with treatment-resistant depressive illness who had not received neurosurgery (Non-Surgical Patient Group 2, NSPG2). We also recruited a further group of 21 controls (Control Group 2, CG2) as CG1 volunteers had not participated in Stroop testing. Fifteen ACING patients participated in total with five taking part in both studies. We therefore included data from 94 unique subjects in the analyses. We collected other neuropsychological data in both studies using the CANTAB (Cambridge Cognition Ltd), which will be reported elsewhere.

Recruitment of patients from the AIS who had received ACING meant that patients satisfied the following criteria at the time of neurosurgery (Steele et al., 2008): diagnosis of F32.2 severe depressive episode without psychotic symptoms; F32.3 severe depressive episode with psychotic symptoms; F33.1 to F33.3 recurrent depressive disorder current episode moderate-to-severe; F31.4 to F31.5 bipolar affective disorder, current episode severe depression with or without psychotic symptoms. The patient had to be capable of providing sustained informed consent. The criteria for exclusion were a current diagnosis of substance misuse fulfilling criteria for ICD-10 F10 to F19 mental and behavioural disorders due to psychoactive substance use, a diagnosis of organic brain syndrome fulfilling criteria for ICD-10 F00 to F09 including Alzheimer’s disease, vascular and other dementias, a diagnosis of Adult Personality Disorder fulfilling criteria for ICD-10 F60 to F69, and a diagnosis of Pervasive Developmental Disorder fulfilling criteria for ICD-10 F84.

Non-surgical patients with depressive illness satisfied similar criteria and controls were matched on the basis of age, male/female ratio and NART. These patients were also recruited from the AIS and included patients who later proceeded to ACING plus others in long-term follow-up by secondary care Community Mental Health Care (CMHT) services. As is typical for patients with treatment-resistant mood disorder attending the AIS, patients almost always had one episode of illness, which they had suffered from for decades, with incomplete recovery despite multiple treatment trials. Non-surgical patients were matched to patients receiving ACING (Study 2) on the basis of medication exposure using the MGH-S. Controls were recruited from friends and relatives of patients. Advertisement was not used for recruitment. No subjects had co-morbid pain syndromes.

Study 1: Emotional facial recognition task

A test from the Facial Expressions of Emotion: Stimuli and Tests (FEEST) was used to assess the ability to recognize facial expressions of emotions (Young et al., 2002). The Ekman 60 Faces (E60F) (Fig. 1) test uses photographs of the faces of 10 people from the Ekman series (Eckman and Friesen, 1976). For each face, there are facial expressions of
six basic emotions: happiness, surprise, fear, sadness, disgust, and anger, giving a total of 60 pictures with 10 for each emotion. Negative affect expressions were defined as fear, disgust, anger and sadness; positive or neutral expressions as happiness and surprise.

**Study 2: Stroop tasks**

Two versions of the Stroop task were used, an emotionally neutral colour naming Stroop task (classic Stroop) and an Emotional Face Stroop task (EFS) (Fig. 1). The classic Stroop task involves naming the colour of the ink (e.g. red or blue) that a colour word (‘red’ or ‘blue’) is written in. Congruent trials consist of the word being written in the same colour of ink, incongruent trials with the word written in a different colour of ink. In incongruent trials, interference between the word and ink colour results in increased errors and reaction times (Stroop, 1935).

Different ‘emotional’ versions of the Stroop task exist. In one of the most common types, slower naming of the colour an
emotional word is written in (e.g. ‘war’, ‘kill’) occurs, involving an effect of the emotional relevance of the word, but without a conflict with word meaning. We wished to use a version of the Stroop that does involve an explicit conflict with meaning, analogous to the classic Stroop task. Therefore the EFS task we chose involved incongruent trials (e.g. picture of a sad face and the word ‘happy’ underneath) and congruent trials (e.g. picture of a sad face and the word ‘sad’ underneath) (Saunders and Jentzsch, 2014). Incongruent trials, requiring increased cognitive control to minimize errors, tend to activate the aMCC (Shackman et al., 2011). The ‘Stroop effect’ was defined for both classic Stroop and EFS tasks as the difference in the total number of errors: (incongruent — congruent) conditions.

Neuroimaging

For each participant structural T2-weighted brain scans were acquired at least a year after ACING when radiological appearances are stable with lesions quantified using the method we described previously (Steele et al., 2008). Briefly, each T2-weighted image was segmented into separate grey and white matter and CSF images and spatially normalized to Montreal Neurological Institute (MNI) anatomical space using SPM8 (Friston et al., 2007). In T2-weighted images, ACING lesions have a voxel intensity corresponding to CSF. For each subject and blind to outcome using MRICron (http://www.mccausland-center.sc.edu/mricron/mricron/), the spatially normalized and segmented CSF images were viewed in transverse section. ACING lesions were outlined in each hemisphere and a list of voxel coordinates in MNI space obtained at 1 mm spacing, defining each lesion volume in cubic millimetres (Steele et al., 2008). For each subject, lesion volume was visualized using MRICron and the overlap between each binary map (cognitive control or negative affect) and lesion volume was output as a list of voxel coordinates in MNI space, with overlap volume being the total number of coordinates multiplied by the voxel volume. Cognitive control and negative affect binary masks, lesion volumes and overlap regions are shown for representative subjects in Fig. 1.

Analyses: Study 1

Between groups

For patients (SPG1), the total number of errors in detecting each of the six emotions was compared to controls (CG1) and the null hypothesis of no difference tested using t-tests. This calculation was done for both preoperative baseline and postoperative follow-up assessment.

First a priori hypothesis

For each of the six emotions, a linear regression was calculated with the volume of overlap (between each patient’s lesions and Shackman’s negative affect binary mask) as the dependent variable (overlap negative affect), and number of emotion recognition errors as the first independent variable, depressive illness severity at the time of testing (MADRS or HAM-17) as the second independent variable and number of ACING procedures as the third independent variable. These covariates were included as both illness severity and number of operations correlated with total emotion recognition errors.

Analyses: Study 2

Between groups

For patients (SPG2), Stroop effect total errors for the classic Stroop and EFS tasks were tested using an ANOVA with the main effects group (SPG2, NSPG2 and control) and task type (classic Stroop versus EFS) and their interaction with covariates MADRS, HAM-17, HAD-A and number of ACING operations.

Second a priori hypothesis

A linear regression was done with the volume of overlap (between each patient’s lesions and Shackman’s cognitive control binary mask) as the dependent variable (overlap cognitive control, overlap cognitive control), and the total classic Stroop and EFS Stroop effect error rate as the first independent variable, depressive illness severity (MADRS or HAM-17) as the second independent variable and number of ACING procedures as the third independent variable.

Specificity of Shackman masks

Third hypothesis

This was tested with linear regressions as above, but with total lesion volume as the dependent variable.

Fourth hypothesis

This was tested with total volume of overlap (between each patient’s ACING lesion and the cognitive control binary mask, overlap cognitive control) as the dependent variable, and the total number of facial recognition errors as the first independent variable, depressive illness severity (MADRS or HAM-17) as the second independent variable and number of ACING procedures as the third independent variable. We also tested whether the total volume of overlap (between each patient’s ACING and the negative affect binary mask, overlap negative affect) was significantly related to the total number of Stroop errors, taking account of depressive illness severity (MADRS or HAM-17) and number of ACING procedures.

Correction for post hoc testing

We only had two a priori regions of interest per patient: overlaps between Shackman’s masks (negative affect and cognitive control) and ACING lesion. In addition we only had one strong a priori hypothesis for each region of interest based on the cited literature. In Study 1 we had no specific hypotheses about any individual emotion and instead we had one a priori hypothesis about negatively valenced emotions in general. We did not draw conclusions about any specific emotion. In Study 2 we similarly only had one a priori hypothesis about increased Stroop errors. Consequently, we did not use post hoc correction for linear regression testing of the two a priori hypotheses. It was possible to apply correction to the third and fourth hypotheses but this was not done to have a low threshold for detecting non-specificity of the masks. Other tests had less a priori basis so Bonferroni correction was applied.
Results

Participants

Groups were matched on the bases of male/female ratio, age and NART. In Study 1, there were no significant differences in male/female ratio ($\chi^2 = 1.7$, $P = 0.19$), age ($t = 0.13$, $P = 0.89$) or NART ($t = 1.5$, $P = 0.1$). Similarly, in Study 2 there were no significant differences in male/female ratio ($\chi^2 = 2.1$, $P = 0.3$), age ($F = 1.6$, $P = 0.2$) or NART ($F = 0.3$, $P = 0.7$).

As shown in Table 1, MGH-S scores of 15.9 to 17.3 for patients receiving ACING indicated a very high level of treatment resistance, similar to previous studies of patients attending the AIS (15.6) (Steele et al., 2008), in contrast to much less treatment-resistant secondary care 6.9 and primary care patients 0.54 (Hazari et al., 2013). SF-36 ratings (30 ± 12 and 44 ± 15) indicated marked quality of life impairments in patients with treatment-resistant depression before surgery (SPG1) (Table 1).

Patients satisfied ICD-10 criteria for recurrent unipolar depressive disorder unless in remission. With ACING ‘response’ defined as a reduction of 50% or more at 1 year compared to baseline HAM-17 and MADRS scores (Steele et al., 2008), ACING responders ($n = 6$ Study 1, $n = 5$ Study 2) had SF-36 scores of 60 ± 13 and 88 ± 10, respectively, and non-responders ($n = 6$ Study 1, $n = 3$ Study 2) 31 ± 14 and 35 ± 20, respectively. Combined responder and non-responder scores are shown in Table 1. These scores can be compared with other severe chronic illnesses: 72, 55, 36 for congestive heart failure (New York Heart Association, NYHA, Classes 1, 2, 3, respectively), 62 for hepatitis and in addition, 51 for non-treatment resistant depression with 89 for controls (Juenger et al., 2002).

Analyses: Study 1

Preoperative baseline and follow-up illness severity (MADRS, HAM-17, HAD-A) plus estimated IQ (NART) are shown in Table 1. This indicates that patients had a depressive illness in the ‘moderate-severe’ range before their operation and illness severity had on average decreased significantly at long-term follow-up (MADRS, $t = 3.04$, $P = 0.014$, HAM-17, $t = 2.5$, $P = 0.02$). There was no significant change in estimated IQ.

Between groups’ analyses

The average number of errors made by subjects (standard deviation in brackets) for recognition of different emotions is shown in Table 2. In comparison to controls, at preoperative baseline, patients made significantly more errors in recognizing expressions of disgust ($t = 2.2$, $P = 0.01$) but not any other emotions ($t = 1.6$, $P > 0.05$). In contrast and in comparison to control subjects, patients at follow-up made significantly more errors in recognizing expressions of fear ($t = 1.6$, $P = 0.004$) but no other emotions ($P > 0.05$). Only postoperative impairment in fear recognition remained significant after Bonferroni correction ($P = 0.048$).

Within patient group correlations

As depressive illness can be associated with cognitive impairment, we did exploratory tests for correlations between errors in recognizing different emotional expressions and illness severity at baseline and follow-up. At preoperative baseline, fear, anger and disgust recognition errors correlated positively with HAM-17 illness severity ($r = 0.62$, $P = 0.05$; $r = 0.74$, $P = 0.01$; $r = 0.67$, $P = 0.05$, respectively). At follow-up, HAM-17 and MADRS also correlated positively with anger recognition errors ($r = 0.63$, $P = 0.05$; $r = 0.58$, $P = 0.05$). There were no significant correlations with anxiety (HAD-A) scores. There was a positive correlation between increased fear recognition errors and number of ACING procedures ($r = 0.78$, $P = 0.02$). There were no correlations with NART IQ score at either baseline or follow-up.

First a priori hypothesis

When illness severity (quantified by either MADRS or HAM-17) and number of ACING procedures were ‘covariated out’, there was a significant relationship (Table 3) between overlap negative affect and impairment in

Table 1 Demographic and clinical characteristics

<table>
<thead>
<tr>
<th></th>
<th>CGI Baseline</th>
<th>SPG1 Baseline</th>
<th>SPG1 Follow-up</th>
<th>CG2</th>
<th>NSPG2</th>
<th>SPG2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>50.9 (8.3)</td>
<td>50.63 (5.0)</td>
<td>51.63 (5.0)</td>
<td>46.1 (14)</td>
<td>51.80 (11.23)</td>
<td>53.1 (7.4)</td>
</tr>
<tr>
<td>Male/female</td>
<td>14/24</td>
<td>2/10</td>
<td>2/10</td>
<td>6/15</td>
<td>5/15</td>
<td>0/8</td>
</tr>
<tr>
<td>NART</td>
<td>121.7 (5.7)</td>
<td>117.6 (7.4)</td>
<td>118.6 (7.8)</td>
<td>122.8 (5.8)</td>
<td>122.75 (4.7)</td>
<td>124.4 (5.2)</td>
</tr>
<tr>
<td>MADRS</td>
<td>-</td>
<td>42.25 (5.9)</td>
<td>28.58 (16.7)</td>
<td>0.48 (1.03)</td>
<td>22.50 (7.97)</td>
<td>17.13 (16.7)</td>
</tr>
<tr>
<td>HAM-17</td>
<td>-</td>
<td>27.9 (4.9)</td>
<td>19.7 (10.5)</td>
<td>1.3 (1.5)</td>
<td>16.10 (5.58)</td>
<td>15.9 (7.8)</td>
</tr>
<tr>
<td>HAD-A</td>
<td>-</td>
<td>13.1 (4.7)</td>
<td>11.33 (6.5)</td>
<td>8.8 (6.8)</td>
<td>11.05 (3.9)</td>
<td>8.4 (6.8)</td>
</tr>
<tr>
<td>MGH-S</td>
<td>N/A</td>
<td>16.3 (3.5)</td>
<td>16.3 (3.5)</td>
<td>N/A</td>
<td>13.24 (10.78)</td>
<td>15.3 (1.98)</td>
</tr>
<tr>
<td>SF-36</td>
<td>-</td>
<td>30.1 (12.3)</td>
<td>45.6 (20.1)</td>
<td>93.5 (4.0)</td>
<td>44.2 (14.9)</td>
<td>55.4 (33)</td>
</tr>
</tbody>
</table>

SPG1 = Surgical Patient Group 1; CGI = Control Group 1; SPG2 = Surgical Patient Group 2; CG2 = Control Group 2; NSP = non-surgical patients; NS = not significant; N/A = not applicable; - = not available.

Values are mean (standard deviation).
identifying negative emotions of fear, disgust and anger, but not sadness, and no relationship between overlap and expressions of happiness or surprise. Bonferroni correction was not used as these were a priori planned tests. Figure 2 shows partial regression plots for overlap negative affect versus total errors for fear, disgust and anger.

**Analyses: Study 2**

Clinical and demographic details for controls (CG2), patients with depression who had not received ACING (NSPG2), and patients who had received ACING as treatment (SPG2), are shown in Table 1.

There was a significant main effect of Group with regard to MADRS ($F = 28.9$, $P < 0.001$), HAM-17 ($F = 30.5$, $P < 0.001$), HAD-A ($F = 26.1$, $P < 0.001$) but not NART ($F = 0.6$, $P = 0.55$). Post hoc pair-wise comparisons after Bonferroni correction revealed significant differences in: (i) MADRS scores between the SPG2 and CG2 ($P < 0.001$) and between NSPG2 and CG2 ($P < 0.001$). No interaction was found for type of task ($P = 0.8$) therefore classic Stroop and EFS data were pooled.

This indicates that patients with depressive illness who had received ACING had less depressive symptoms than those who had not and there were no significant differences in IQ between groups.

**Table 2 Errors on emotional facial recognition and Stroop tasks**

<table>
<thead>
<tr>
<th>Errors</th>
<th>CG1</th>
<th>SPG1</th>
<th>SPG2</th>
<th>CG2</th>
<th>NSPG2</th>
<th>SPG2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fear</td>
<td>2.76 (2)</td>
<td>3 (2.5)</td>
<td>4.3 (2.4)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Disgust</td>
<td>1.05 (1.3)</td>
<td>2.1 (1.2)</td>
<td>2.2 (1.8)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anger</td>
<td>1.89 (7.8)</td>
<td>2.2 (1.9)</td>
<td>2.2 (2)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sadness</td>
<td>1.97 (4.6)</td>
<td>2 (1.1)</td>
<td>2.1 (1.5)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Surprise</td>
<td>1.16 (1.1)</td>
<td>1 (1.7)</td>
<td>1.5 (1.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Happiness</td>
<td>0.01 (0.3)</td>
<td>0.2 (0.4)</td>
<td>0 (0)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stroop effect errors</td>
<td>8.2 (5.9)</td>
<td>13.7 (6.6)</td>
<td>20.27 (20.4)</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stroop effect reaction time</td>
<td>51.15 (35.1)</td>
<td>92.10 (67.2)</td>
<td>100.3 (72.25)</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Values are mean (standard deviation).
- = not available.

**Table 3 Emotional facial recognition lesion overlap**

<table>
<thead>
<tr>
<th>Errors</th>
<th>β</th>
<th>$P$-value</th>
<th>MADRS</th>
<th>β</th>
<th>Sig.</th>
<th>HAMD</th>
<th>β</th>
<th>Sig.</th>
<th>Number of procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fear</td>
<td>0.6</td>
<td>0.03*</td>
<td>0.5</td>
<td>0.6</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td>Disgust</td>
<td>0.5</td>
<td>0.02*</td>
<td>0.09</td>
<td>0.7</td>
<td></td>
<td>0.6</td>
<td>0.02*</td>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td>Anger</td>
<td>0.6</td>
<td>0.02*</td>
<td>0.07</td>
<td>0.8</td>
<td></td>
<td>0.2</td>
<td>0.4</td>
<td></td>
<td>0.6</td>
</tr>
<tr>
<td>Sadness</td>
<td>0.1</td>
<td>0.035*</td>
<td>0.4</td>
<td>0.3</td>
<td></td>
<td>0.2</td>
<td>0.4</td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>Happiness</td>
<td>0.4</td>
<td>0.15</td>
<td>0.4</td>
<td>0.2</td>
<td></td>
<td>0.5</td>
<td>0.07</td>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td>Surprise</td>
<td>0.4</td>
<td>0.13</td>
<td>0.4</td>
<td>0.2</td>
<td></td>
<td>0.5</td>
<td>0.08</td>
<td></td>
<td>0.3</td>
</tr>
<tr>
<td>Stroop effect errors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.4</td>
<td>0.1</td>
<td></td>
<td>0.3</td>
</tr>
</tbody>
</table>

Values are mean (standard deviation).
- = not available.

$\beta =$ regression parameters; *$P < 0.05$.

Within SPG2 group correlations

Linear regressions were used to test for a relationship between Stroop effect errors and symptom severity scores in the SPG2 group alone. Stroop effect errors correlated significantly with MADRS ($t = 2.7$, $P = 0.018$), HAM-17 ($t = 5.9$, $P = 0.001$) and HAD-A ($t = 2.9$, $P = 0.023$) between the SPG2 and CG2 ($P < 0.001$) and between NSPG2 and CG2 ($P < 0.001$).
scores. This indicates that more ill patients made more Stroop effect errors. There was no relationship with number of ACING procedures ($t = 1.4$, $P = 0.2$).

**Second a priori hypothesis**

Similar to emotional facial recognition, we tested the hypothesis of a significant positive relationship between overlap cognitive control and total Stroop errors, taking account of illness severity and number of operations. There was a significant positive relationship between cognitive control mask overlap and Stroop effect errors ($\beta = 1.2$, $P = 0.03$) as shown in Fig. 2.

**Specificity of masks**

**Third hypothesis**

We tested whether lesion volume was significantly associated with emotional facial expression recognition accuracy or Stroop task accuracy, taking into account illness severity and number of ACING procedures. There were no significant correlations between total lesion volume and recognition of fear ($r = -1.6$, $P = 0.15$), disgust ($r = 0.3$, $P = 0.78$), anger ($r = -1.56$, $P = 0.16$), sadness ($r = -0.198$, $P = 0.85$), surprise ($r = -0.83$, $P = 0.43$), or happiness ($r = 0.75$, $P = 0.48$). Similarly, there were no significant correlations between total lesion volume and Stroop effect errors ($r = 2.2$, $P = 0.09$). This indicates that total lesion volume, which includes both grey and white matter, was not systematically related to impairments in emotional facial recognition or cognitive control.

**Fourth hypothesis**

There was no relationship between overlap cognitive control and any other emotions, such as fear ($r = 3.6$, $P = 0.1$), disgust ($r = 0.5$, $P = 0.7$), anger ($r = 0.09$, $P = 0.5$), sadness ($r = 0.02$, $P = 0.96$), surprise ($r = -0.3$, $P = 0.4$), and happiness ($r = 0.4$, $P = 0.15$). Similarly, there was no significant correlation between overlap negative affect and Stroop effect errors ($r = 4.2$, $P = 0.4$). This indicates that small differences between the negative affect and cognitive control masks were important for predicting the observed impairments.

**Discussion**

Negative affect, cognitive control and pain have been strongly linked to the aMCC (Peyron *et al.*, 2000; Shackman *et al.*, 2011; Vogt, 2014). Clinically, ACING lesions within the aMCC have long been used as treatment for otherwise treatment-resistant mood and anxiety disorders (e.g. OCD) (Dougherty *et al.*, 2002; Steele *et al.*, 2008) and chronic pain syndromes (Pereira *et al.*, 2014).

Consistent with our hypotheses, we found that increased volume of overlap between ACING lesions and the negative affect map (overlap negative affect) predicted impaired recognition of negative emotions of fear, disgust and anger and no impairment in recognizing facial expressions of surprise or happiness. In addition, we found that increased volume of overlap between ACING lesions and the cognitive control map predicted increased Stroop effect errors.

---

*Figure 2* Lesion volume mask overlap versus total error partial regressions. Overlap versus total errors on recognizing (A) fear, (B) disgust and (C) anger emotional expressions. (D) Overlap versus total Stroop errors.
Only the overlap between ACING lesions and the negative affect map was associated with impairments in recognizing facial expressions of negative affect and Stroop effect errors, not total ACING lesion volume or when using the cognitive control mask, supporting the specificity of Shackman's grey matter-linked map functions.

Contrary to predictions, we did not find that overlap negative affect was associated with impaired accuracy in identifying emotional expressions of sadness. However, Vogt et al. (2003) highlighted fear and pain as being particularly associated with aMCC function, but not sadness, which they linked to the subgenual cingulate region. Our results support the suggestion that the aMCC is less directly associated with sadness than other negative emotions, such as fear.

Extensive cross-species data link the amygdala to the acquisition and expression of conditioned fear, with rodent studies also implicating the prelimbic region of the medial frontal cortex, which is homologous with the aMCC in humans (Milad et al., 2007). The aMCC projects to the amygdala (Vogt, 2009) with these projections being excitatory (Brinley-Reed et al., 1995). In humans, the aMCC was reported to be activated by a conditioned fear stimulus with aMCC cortical thickness being positively correlated with skin conductance response during aversive electrical shock conditioning (Milad et al., 2007). Notably, the aMCC also projects directly to the peri-aqueductal grey (PAG) (Vogt, 2009), which is strongly associated with pain and fear (Graeff, 2004). Patients receiving ACING in Study 1 were significantly impaired in recognizing facial expressions of fear. Further supporting a link between the aMCC and fear, recently it has been reported that transient electrical stimulation of the most anterior part of the aMCC (MNI coordinate system, anterior–posterior range \(y = 20–26\)) was associated with induced feelings of ‘shakiness’ and ‘a sense of “challenge” or “worry” (also known as foreboding)’ and ‘feeling worried and anxious that something negative was going to happen’ (Parvizi et al., 2013). In contrast, more posterior (MNI \(y = 0–18\)) aMCC transient electrical stimulation was reported to induce ‘complex’, ‘stereotyped’ behaviours, ‘invariably involuntary, sometimes the subject was able to resist performing them, sometimes not’, but usually without clear effects on emotion (Talairach et al., 1973). Talairach’s description of induced behaviours is reminiscent of compulsions occurring in OCD and ACING is also used to treat otherwise intractable OCD. The anterior versus posterior MCC stimulation effects are consistent with reports of the anterior but not the posterior MCC being associated with emotion (Vogt et al., 2003).

Theoretical accounts of the MCC have considered whether this structure is simply involved in detecting conflict or whether it resolves and controls conflict. Shackman and colleagues (2011) proposed that the aMCC processes both punishment-linked information and facilitates actions that avoid future punishment. They formulated this as the Adaptive Control Hypothesis (ACH) noting that negative affect, anxiety and pain tend to engage the same processes described by theories of cognitive control to resolve similar challenges (Shackman et al., 2011). In particular, cognitive control tends to be engaged when habitual responses are insufficient to allow goal-directed behaviour, particularly when there is uncertainty and conflict about the optimal course of action. Notably, studies on patients receiving ACING for treatment-resistant psychiatric disorders have reported individual neurons in the aMCC encoding response conflict information (Davis et al., 2005; Sheth et al., 2012) and individual neuronal firing that was predictive of motor actions (Williams et al., 2004). This and the results of the present study suggest that the MCC is involved in resolution and control of conflict supporting the ACH.

Behavioural errors are associated with an electrophysiological event-related potential, the error-related negativity (ERN). This signal is thought to reflect a discrepancy between representations of actual and correct actions and the ERN has been linked to MCC function (Riesel et al., 2013; Cavanagh and Shackman, 2015). The ERN was reported to be abnormally reduced in a patient with a rare naturally occurring lesion of the MCC (Swick and Turken, 2002). A recent review concluded that the ERN is abnormally increased in OCD, depression and generalized anxiety disorder, and an increased ERN is associated with high trait anxiety and high negative affect (Weinberg et al., 2012).

The ERN is one of several MCC-related behavioural control signals, and spectral decomposition has shown that the ERN, the ‘feedback-related negativity’ which is linked to punishment, and the ‘N2’, which is linked to conflict, share a common component in the theta band of the electroencephalogram (Cavanagh and Shackman, 2015). It has been proposed that frontal midline theta signals reflect MCC activity, being part of the neural mechanism for optimally adjusting behaviour to uncertainty, a characteristic of events that cause anxiety and require cognitive control (Cavanagh and Shackman, 2015). Recently a large international study has concluded that patients with depressive illness have abnormally increased frontal and rostral anterior cingulate theta compared to controls, which the authors suggest is a potential endophenotype of depressive illness (Arns et al., 2015).

Consequently, there is convergent evidence that the aMCC is an important part of a network linked to the experience of negative affect which engages cognitive control processes for optimizing behaviour. In this context, our finding that increased lesion volume was linked to increased impairment in recognizing facial expressions of negative affect, but not positive or neutral affect, and impairment in Stroop cognitive control, supports the assertion that the aMCC has a causal role in these processes. Importantly, however, these abnormalities were only detectable on neuropsychological testing and not clinically. The therapeutic benefit of a reduction in negative affect may be associated with a reduction in cognitive control. However depressive illness has been reported to be associated with Stroop impairments independent of any lesion and we found correlations with illness severity in the present study. Therefore with ACING it is possible that
any reduction in cognitive control is offset by an improvement in mood. Before receiving ACING, patients were ill long-term, highly treatment-resistant and had an SF-36 measured quality of life comparable to patients with very disabling diseases. AIS patients with treatment-resistant depression typically have an ACING ‘response’ rate of 62% (Steele et al., 2008) and for those who responded, this was associated with a substantially improved quality of life. Further work on understanding the normal function of the aMCC, and abnormal function in depressive illness, may allow the development of improved surgical techniques and outcomes.

A possible limitation is the small number of subjects. ACING is, however, a treatment of last resort, carried out in a limited number of centres worldwide, therefore the number of patients available for testing is limited. Furthermore, recruitment criteria and ACING procedures differ between centres complicating independent replication. To our knowledge we report data on more patients who have received ACING than previously. Medication exposure, quantified using the MGH-S score, has potential limitations. It’s not known if different medications given long-term and in combination have different effects on facial affect recognition independent of illness severity in treatment-resistant illness.

In summary, it has been proposed that the aMCC is linked to the experience of negative affect and cognitive control (Shackman et al., 2011; Vogt, 2014). As hypothesized, we found that aMCC overlap volume was linked to impaired recognition of facial expressions of negative affect, in particular fear, disgust and anger, but not positive or neutral emotions. Also as hypothesized, the aMCC overlap volume was significantly related to impaired performance on Stroop tasks reflecting impaired cognitive control. While the clinical justification for ACING is empirical and not theoretical, it is plausible that lesions within a brain region associated with the subjective experience of negative affect and pain (Shackman et al., 2011; Vogt, 2014) may be therapeutic for patients with otherwise intractable mood, anxiety and pain syndromes.

Acknowledgements

We thank Christine Matthews for helping with accessing data and Mairi Stirling, Karen Walker and Craig Adam for their help during recruitment.

Funding

The project was supported by awards from an Anonymous Trust and by the Scottish Mental Health Research Network (SMHRN). B.J. was partially supported by a SINAPSE (www.sinapse.ac.uk) studentship, which included a SINAPSE-SPIRIT industry partnership with Siemens Medical, while this work was undertaken. S.T. has received research project funding from Lundbeck and Merck Serono. K.M. has Chaired advisory boards for studies of Deep Brain Stimulation for Obsessive-Compulsive Disorder sponsored by Medtronic. He has received educational grants from Cyberonics Inc. and Schering Plough, and he has received research project funding from Lundbeck, Merck Serono and Reckitt Benckiser and also from St Jude Medical for a multi-centre clinical trial of Deep Brain Stimulation for depression. He has received travel and accommodation support to attend meetings from Medtronic and St Jude Medical. J.D.S. has received research funding via an honorarium associated with a lecture from Wyeth. I.J. and R.S. report no biomedical financial interests or potential conflicts of interest. The funding sources played no part in the design of the study, analysis and interpretation of the data, nor manuscript preparation.

Conflict of interest

S.T. has received research project funding from Lundbeck & Merck Serono. K.M. has Chaired advisory boards for studies of Deep Brain Stimulation for Obsessive-Compulsive Disorder sponsored by Medtronic. He has received educational grants from Cyberonics Inc. & Schering Plough, and he has received research project funding from Lundbeck, Merck Serono & Reckitt Benckiser and also from St Jude Medical for a multi-centre clinical trial of Deep Brain Stimulation for depression. He has received travel and accommodation support to attend meetings from Medtronic and St Jude Medical. J.D.S. has received research funding via an honorarium associated with a lecture from Wyeth.

References


